New Approaches for the Prevention and Alleviation of Metabolic Syndrome 2024
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 20 June 2024 | Viewed by 695
Special Issue Editor
Interests: lipid metabolism; metabolic disorder of post-menopausal women; free radical research; diabetes; obesity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Metabolic syndrome is defined as a cluster of conditions characterized by impaired glucose metabolism, hypertension, central obesity, low LDL-C, and high triglyceride levels. It also promotes glucose intolerance and chronic systemic inflammatory conditions characterized by immune cell infiltration, and this immune system activation increases the risk of serious disease following viral infection. In addition, studies have been reported regarding an increase in diseases associated with various metabolic disorders, such as nonalcoholic fatty liver, psoriasis, and IBD. Metabolic disease tends to progress quietly and gradually, rather than with acute symptoms. Due to the recent COVID-19 pandemic, increased processed food and salt intake, surplus energy accumulation, sedentary lifestyle, and reduced physical activity are thought to be risk factors for an increase in metabolic disease. Therefore, the discovery of drugs related to metabolic diseases and metabolic disorders has an important meaning in this difficult period. I hope that this Special Issue will provide an opportunity to help all patients and further the development of the scientific community. In order to achieve this, the cooperation of all our valuable colleagues, including yourself, is essential.
We are pleased to welcome papers reviewing the most recent research on this topic in the present thematic issue.
We look forward to your contribution.
Dr. Seong-Hee Maria Ko
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metabolic disorder
- IBD
- diabetes
- hypertension
- obesity
